Outcome in pediatric celiac disease is independent of the diagnostic approach in patients with high antibody levels

Abstract

AbstractObjectivesEuropean Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines enable the diagnosis of celiac disease (CD) without biopsies in patients with immunoglobulin A (IgA)‐antibodies against tissue transglutaminase (TGA‐IgA) ≥ 10× the upper limit of normal (ULN) and positivity of endomysial antibodies in a second blood sample. Limited data exist comparing the biopsy versus the nonbiopsy diagnostic approach regarding long‐term outcomes in CD patients. Our study aimed to investigate the influence of the diagnostic approach on adherence to gluten‐free diet (GFD), serological remission (defined as normalization of TGA‐IgA during follow‐up (FU)) and clinical remission in CD patients with TGA‐IgA ≥ 10× ULN.MethodsRetrospective multicenter study. Patients with CD and TGA‐IgA ≥ 10× ULN at diagnosis were included in the study. Patients with confirmed diagnosis by biopsy were compared to patients diagnosed by nonbiopsy approach using univariate analysis, Kaplan–Meier survival curve, and logistic regression models.ResultsA total of 282 CD patients (192 [68.1%] in the biopsy group; 90 [31.9%] in the nonbiopsy group) were analyzed. The median time to normalization of TGA‐IgA was 16.5 months [interquartile range, IQR: 13, 28] in the biopsy and 15 months [IQR: 12, 26] in the nonbiopsy group; p = 0.14). Rates of normalized TGA‐IgA at first to third‐year FU were comparable between both groups. Adherence to GFD did not seem to be influenced by the diagnostic approach.ConclusionsThe nonbiopsy approach is not inferior to the biopsy approach in terms of adherence to GFD and serological remission in patients with CD.